These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 8450038)

  • 1. Immune complexes from immunized mice and infected cystic fibrosis patients mediate murine and human T cell killing of hybridomas producing protective, opsonic antibody to Pseudomonas aeruginosa.
    Pier GB; Takeda S; Grout M; Markham RB
    J Clin Invest; 1993 Mar; 91(3):1079-87. PubMed ID: 8450038
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mucoid Pseudomonas aeruginosa growing in a biofilm in vitro are killed by opsonic antibodies to the mucoid exopolysaccharide capsule but not by antibodies produced during chronic lung infection in cystic fibrosis patients.
    Meluleni GJ; Grout M; Evans DJ; Pier GB
    J Immunol; 1995 Aug; 155(4):2029-38. PubMed ID: 7636254
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rationale for development of immunotherapies that target mucoid Pseudomonas aeruginosa infection in cystic fibrosis patients.
    Pier GB
    Behring Inst Mitt; 1997 Feb; (98):350-60. PubMed ID: 9382760
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nonopsonic antibodies in cystic fibrosis. Pseudomonas aeruginosa lipopolysaccharide-specific immunoglobulin G antibodies from infected patient sera inhibit neutrophil oxidative responses.
    Eichler I; Joris L; Hsu YP; Van Wye J; Bram R; Moss R
    J Clin Invest; 1989 Dec; 84(6):1794-804. PubMed ID: 2512330
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Complement deposition by antibodies to Pseudomonas aeruginosa mucoid exopolysaccharide (MEP) and by non-MEP specific opsonins.
    Pier GB; Grout M; Desjardins D
    J Immunol; 1991 Sep; 147(6):1869-76. PubMed ID: 1832427
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Construction and characterization of a Pseudomonas aeruginosa mucoid exopolysaccharide-alginate conjugate vaccine.
    Theilacker C; Coleman FT; Mueschenborn S; Llosa N; Grout M; Pier GB
    Infect Immun; 2003 Jul; 71(7):3875-84. PubMed ID: 12819072
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cross-sectional and longitudinal studies of naturally occurring antibodies to Pseudomonas aeruginosa in cystic fibrosis indicate absence of antibody-mediated protection and decline in opsonic quality after infection.
    Tosi MF; Zakem-Cloud H; Demko CA; Schreiber JR; Stern RC; Konstan MW; Berger M
    J Infect Dis; 1995 Aug; 172(2):453-61. PubMed ID: 7622889
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlation between specific IgG subclass antibodies to Pseudomonas aeruginosa and opsonic activity in serum from patients with cystic fibrosis.
    Pressler T; Jensen ET; Espersen F; Pedersen SS; Høiby N; Koch C
    Pediatr Pulmonol; 1994 Jan; 17(1):31-40. PubMed ID: 8108174
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pseudomonas aeruginosa surface polysaccharide vaccines. New therapeutic approaches from basic research.
    Pier GB
    Antibiot Chemother (1971); 1985; 36():157-67. PubMed ID: 3923913
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Anti-Pseudomonas aeruginosa antibodies, circulating immune complexes, and anticytoplasm antibodies of neutrophils in patients with cystic fibrosis with and without Pseudomonas aeruginosa colonization].
    Chiappini E; Taccetti G; Campana S; Turchini S; Marianelli L
    Pediatr Med Chir; 2001; 23(1):27-30. PubMed ID: 11486418
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induction of opsonic antibodies to Pseudomonas aeruginosa mucoid exopolysaccharide by an anti-idiotypic monoclonal antibody.
    Schreiber JR; Pier GB; Grout M; Nixon K; Patawaran M
    J Infect Dis; 1991 Sep; 164(3):507-14. PubMed ID: 1831226
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of alginate O acetylation in resistance of mucoid Pseudomonas aeruginosa to opsonic phagocytosis.
    Pier GB; Coleman F; Grout M; Franklin M; Ohman DE
    Infect Immun; 2001 Mar; 69(3):1895-901. PubMed ID: 11179370
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human immune response to Pseudomonas aeruginosa mucoid exopolysaccharide (alginate) vaccine.
    Pier GB; DesJardin D; Grout M; Garner C; Bennett SE; Pekoe G; Fuller SA; Thornton MO; Harkonen WS; Miller HC
    Infect Immun; 1994 Sep; 62(9):3972-9. PubMed ID: 8063415
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pulmonary outcome in cystic fibrosis is influenced primarily by mucoid Pseudomonas aeruginosa infection and immune status and only modestly by genotype.
    Parad RB; Gerard CJ; Zurakowski D; Nichols DP; Pier GB
    Infect Immun; 1999 Sep; 67(9):4744-50. PubMed ID: 10456926
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pseudomonas aeruginosa chromosomal beta-lactamase in patients with cystic fibrosis and chronic lung infection. Mechanism of antibiotic resistance and target of the humoral immune response.
    Ciofu O
    APMIS Suppl; 2003; (116):1-47. PubMed ID: 14692154
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Opsonization of mucoid and non-mucoid Pseudomonas aeruginosa by serum from patients with cystic fibrosis assessed by a chemiluminescence assay.
    LeBlanc CM; Bortolussi R; Issekutz AC; Gillespie T
    Clin Invest Med; 1982; 5(2-3):125-8. PubMed ID: 6811181
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nonspecific immunoglobulin synthesis and elevated IgG levels in rabbits immunized with mucoid exopolysaccharide from cystic fibrosis isolates of Pseudomonas aeruginosa.
    Pier GB; Elcock ME
    J Immunol; 1984 Aug; 133(2):734-9. PubMed ID: 6234359
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunogenic properties of Pseudomonas aeruginosa mucoid exopolysaccharide.
    Garner CV; DesJardins D; Pier GB
    Infect Immun; 1990 Jun; 58(6):1835-42. PubMed ID: 2140341
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protection against mucoid Pseudomonas aeruginosa in rodent models of endobronchial infections.
    Pier GB; Small GJ; Warren HB
    Science; 1990 Aug; 249(4968):537-40. PubMed ID: 2116663
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of cytophilic IgG3 antibody in T cell-mediated resistance to infection with the extracellular bacterium, Pseudomonas aeruginosa.
    Markham RB; Pier GB; Schreiber JR
    J Immunol; 1991 Jan; 146(1):316-20. PubMed ID: 1898604
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.